Literature DB >> 18243793

Physiology and pharmacology of the (pro)renin receptor.

Geneviève Nguyen1, Aurélie Contrepas.   

Abstract

The (pro)renin receptor [(P)RR] is a single trans-membrane domain receptor that mediates renin and prorenin specific effects. The receptor acts as co-factor for renin and prorenin by increasing their enzymatic activity on the cell-surface and it activates the mitogen activated protein kinases ERK1/2 cascade leading to cell proliferation and to up-regulation of profibrotic genes expression. Studies in genetically modified animals over-expressing (P)RR suggest a direct role for (P)RR cardiovascular and renal pathologies since rats over-expressing (P)RR in vascular smooth-muscle cells develop high blood pressure and those with an ubiquitous over-expression of (P)RR have glomerulosclerosis and proteinuria. A peptide called "handle region peptide" (HRP) mimicking part of the prosegment of prorenin was claimed to block prorenin binding to (P)RR and its activation. The mechanism of action of HRP and its specificity for (P)RR remains very controversial although infusion of this peptide gave spectacular results by preventing diabetic nephropathy in angiotensin II type1a receptor-deficient mice. In contrast to the other components of the renin angiotensin system, (P)RR is necessary to cell survival and proliferation and a mutation of (P)RR is associated with mental retardation and epilepsy, pointing to an essential role of (P)RR in brain development. The (pro)renin receptor is a more complex protein than anticipated and in depth studies of its functions that are likely not restricted to the renin angiotensin system are needed especially in the perspective of the design of a (P)RR blocker.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18243793     DOI: 10.1016/j.coph.2007.12.009

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  26 in total

1.  Genetic disruption of guanylyl cyclase/natriuretic peptide receptor-A upregulates renal (pro) renin receptor expression in Npr1 null mutant mice.

Authors:  Ramu Periyasamy; Subhankar Das; Kailash N Pandey
Journal:  Peptides       Date:  2019-04-06       Impact factor: 3.750

Review 2.  Interplay between the renin-angiotensin system, the canonical WNT/β-catenin pathway and PPARγ in hypertension.

Authors:  Alexandre Vallée; Bernard L Lévy; Jacques Blacher
Journal:  Curr Hypertens Rep       Date:  2018-06-09       Impact factor: 5.369

3.  Angiotensin II increases the expression of (pro)renin receptor during low-salt conditions.

Authors:  Alexis A Gonzalez; Joel P Womack; Liu Liu; Dale M Seth; Minolfa C Prieto
Journal:  Am J Med Sci       Date:  2014-11       Impact factor: 2.378

Review 4.  Mitochondrial angiotensin receptors and cardioprotective pathways.

Authors:  Nelson Escobales; Rebeca E Nuñez; Sabzali Javadov
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-04-12       Impact factor: 4.733

Review 5.  The renin angiotensin system and the metabolic syndrome.

Authors:  Annette D de Kloet; Eric G Krause; Stephen C Woods
Journal:  Physiol Behav       Date:  2010-04-08

Review 6.  Roles of collecting duct renin and (pro)renin receptor in hypertension: mini review.

Authors:  Alexis A Gonzalez; Minolfa C Prieto
Journal:  Ther Adv Cardiovasc Dis       Date:  2015-03-16

Review 7.  Renin and the (pro)renin receptor in the renal collecting duct: Role in the pathogenesis of hypertension.

Authors:  Alexis A Gonzalez; Minolfa C Prieto
Journal:  Clin Exp Pharmacol Physiol       Date:  2015-01       Impact factor: 2.557

Review 8.  New insights and perspectives on intrarenal renin-angiotensin system: focus on intracrine/intracellular angiotensin II.

Authors:  Jia L Zhuo; Xiao C Li
Journal:  Peptides       Date:  2011-06-14       Impact factor: 3.750

Review 9.  Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: antihypertensive effects and benefits beyond BP control.

Authors:  Carlos M Ferrario
Journal:  Life Sci       Date:  2009-12-01       Impact factor: 5.037

10.  Combination therapy with paricalcitol and trandolapril reduces renal fibrosis in obstructive nephropathy.

Authors:  Xiaoyue Tan; Weichun He; Youhua Liu
Journal:  Kidney Int       Date:  2009-09-16       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.